Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOVX GeoVax Labs	$1.05 +1.0%	$0.99	$0.73 ▼ $11.18	$15.95M	3.47	516,961 shs	278,860 shs
LPTX Leap Therapeutics	$0.37 +3.3%	$0.36	$0.22 ▼ $4.79	$15.35M	-0.17	833,643 shs	831,238 shs
MTVA MetaVia	$0.67 +2.6%	$0.97	$0.63 ▼ $5.30	$13.14M	0.21	423,424 shs	40,487 shs
PALI Palisade Bio	$0.74 -3.2%	$0.73	$0.60 ▼ $5.15	$3.53M	1.46	518,594 shs	49,383 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOVX GeoVax Labs	-0.56%	+2.97%	+2.97%	-39.88%	-42.86%
LPTX Leap Therapeutics	-3.37%	-1.67%	-14.70%	-17.66%	-85.25%
MTVA MetaVia	-2.17%	-17.13%	-15.97%	-55.17%	+65,449,900.00%
PALI Palisade Bio	+4.31%	-5.82%	-4.09%	-4.86%	-84.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOVX GeoVax Labs	3.1634 of 5 stars	3.6	4.0	1.9	1.7	1.3
LPTX Leap Therapeutics	2.574 of 5 stars	3.1	4.0	3.0	0.0	1.3
MTVA MetaVia	2.1061 of 5 stars	3.5	0.0	2.5	0.0	1.3
PALI Palisade Bio	2.4968 of 5 stars	3.5	3.0	2.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOVX GeoVax Labs	3.29	Buy	$11.10	957.14% Upside
LPTX Leap Therapeutics	2.25	Hold	$4.92	1,227.04% Upside
MTVA MetaVia	3.00	Buy	$7.50	1,016.40% Upside
PALI Palisade Bio	3.00	Buy	$12.00	1,530.43% Upside

Current Analyst Ratings Breakdown

Latest PALI, MTVA, GOVX, and LPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	MTVA MetaVia	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/13/2025	PALI Palisade Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/16/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/27/2025	LPTX Leap Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/21/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOVX GeoVax Labs	$5.59M	2.85	N/A	N/A	$3.24 per share	0.32
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$2.35 per share	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	$3.44 per share	N/A
PALI Palisade Bio	$250K	14.12	N/A	N/A	$18.29 per share	0.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOVX GeoVax Labs	-$25.97M	-$3.65	N/A	N/A	N/A	N/A	-809.87%	-349.34%	8/5/2025 (Estimated)
LPTX Leap Therapeutics	-$81.41M	-$1.70	N/A	N/A	N/A	N/A	-116.24%	-93.18%	8/11/2025 (Estimated)
MTVA MetaVia	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	8/13/2025 (Estimated)
PALI Palisade Bio	-$12.30M	-$6.80	N/A	N/A	N/A	N/A	-148.51%	-115.16%	8/11/2025 (Estimated)

Latest PALI, MTVA, GOVX, and LPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MTVA MetaVia	-$0.57	-$0.36	+$0.21	-$0.36	N/A	N/A
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A
5/12/2025	Q1 2025	PALI Palisade Bio	-$0.84	-$0.47	+$0.37	-$0.47	N/A	N/A
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million
3/26/2025	Q4 2024	LPTX Leap Therapeutics	-$0.39	-$0.37	+$0.02	-$0.37	N/A	N/A
3/24/2025	Q4 2024	PALI Palisade Bio	-$2.39	-$0.69	+$1.70	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOVX GeoVax Labs	N/A	4.17	4.17
LPTX Leap Therapeutics	N/A	3.97	3.97
MTVA MetaVia	N/A	2.41	2.41
PALI Palisade Bio	N/A	3.31	3.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOVX GeoVax Labs	6.09%
LPTX Leap Therapeutics	30.46%
MTVA MetaVia	1.37%
PALI Palisade Bio	11.79%

Insider Ownership

Company	Insider Ownership
GOVX GeoVax Labs	1.20%
LPTX Leap Therapeutics	5.40%
MTVA MetaVia	1.05%
PALI Palisade Bio	3.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOVX GeoVax Labs	10	15.19 million	8.90 million	Not Optionable
LPTX Leap Therapeutics	40	41.44 million	36.25 million	Optionable
MTVA MetaVia	8	19.56 million	8.53 million	N/A
PALI Palisade Bio	10	4.80 million	2.68 million	Not Optionable

PALI, MTVA, GOVX, and LPTX Headlines

Recent News About These Companies

Transpire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung disease

June 3 at 1:10 PM | fiercebiotech.com

Palisade Bio Reports Improved Quarterly Losses

June 3 at 12:27 AM | tipranks.com

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and ...

May 28, 2025 | manilatimes.net

Palisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn ...

May 28, 2025 | finanznachrichten.de

Palisade Bio reports positive Phase 1 results for new drug

May 28, 2025 | investing.com

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and ...

May 28, 2025 | morningstar.com

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025 | globenewswire.com

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 6, 2025 | globenewswire.com

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

May 1, 2025 | globenewswire.com

Hyundai’s Next-Gen Hybrid System Offers 45% Boost In Fuel Efficiency

April 21, 2025 | msn.com

Palisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108

April 9, 2025 | markets.businessinsider.com

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

April 9, 2025 | globenewswire.com

Maxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)

March 27, 2025 | markets.businessinsider.com

Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial

March 17, 2025 | finance.yahoo.com

Palisade Bio commences dosing in first UC patient cohort in study of PALI-2108

March 14, 2025 | markets.businessinsider.com

Palisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative Colitis

March 14, 2025 | quiverquant.com

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

March 14, 2025 | globenewswire.com

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

March 12, 2025 | globenewswire.com

Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?

March 7, 2025 | zacks.com

Palisade Bio Participates in Virtual Investor “What This Means” Segment

March 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI, MTVA, GOVX, and LPTX Company Descriptions

GeoVax Labs NASDAQ:GOVX

$1.05 +0.01 (+0.96%)

As of 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Leap Therapeutics NASDAQ:LPTX

$0.37 +0.01 (+3.35%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 -0.01 (-2.83%)

As of 05:08 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

MetaVia NASDAQ:MTVA

$0.67 +0.02 (+2.64%)

As of 04:00 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Palisade Bio NASDAQ:PALI

$0.74 -0.02 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 0.00 (-0.41%)

As of 04:02 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time